Top Stories

Biohaven CEO says drug approval is ‘monumental’ for migraine patients


Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.

The U.S. Food and Drug Administration last week approved the medicine, Nurtec ODT, for preventative treatment of migraines. That comes about a year after Nurtec was first launched to treat the symptoms of debilitating headaches, making it the first pill approved for both acute treatment and prevention, according to Coric.

“This is a monumental approval for Biohaven and patients with migraine,” Coric said in a “Mad Money” interview with Jim Cramer.

“I’ve been practicing medicine for 25 years, and this is the first time we have a single…


Stock futures are flat as S&P 500 remains range-bound near record

Previous article

How Gojek and Tokopedia teamed up in Indonesia’s biggest merger

Next article

You may also like

Leave a Reply

Notify of

More in Top Stories